Chronic Obstructive Pulmonary Disease (COPD) Stocks
Biopharmaceutical and medical technology firms in this sector develop therapeutic interventions and non-invasive hardware designed to manage airflow obstruction and progressive lung degradation. Revenue models rely on high-volume prescription cycles for inhaled bronchodilators, biological anti-inflammatories, and recurring service fees for home oxygen and ventilation monitoring.
As of Oct 23, 2026, Chronic Obstructive Pulmonary Disease (COPD) has 6 US-listed companies worth $734B combined. The median member moved +1.0% over the past week; AZN led at +3.7% and UPB trailed at -0.7%.
Companies in Chronic Obstructive Pulmonary Disease (COPD)
- MRK – Merck & Company Inc, $363B
- AZN – AstraZeneca PLC, $266B
- GSK – GlaxoSmithKline PLC ADR, $103B
- INVA – Innoviva Inc, $1.5B
- UPB – Upstream Bio, Inc., $151M
- LUNG – Pulmonx Corp, $77.3M